Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials

Summary

GBI Research, the leading business intelligence provider, has released its latest research Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials which provides an insight into different endpoints that are used in dermatological clinical trials. The report examines different aspects under clinical trial endpoints in dermatology such as analysis on major marketed drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising drugs with more emphasis on safety, efficacy and clinical trial details, and terminated trial analysis. The company profiling highlights the marketed drugs in dermatology of different companies.

Dermatological disorders are diverse in clinical presentation, severity and epidemiology; and it affects all age groups of both sexes, however; children are more vulnerable and have been studied worldwide. This report details Endpoints- Clinical Trials in Dermatology, highlighting the five major dermatological disorders which are Alopecia, Acne Vulgaris, Herpes Zoster, Candidiasis and Atopic Dermatitis. The classification of the five major dermatological disorders is based upon the number of pipeline molecules present in Phase III stage of development. GBI Research analyses that safety and efficacy is the most widely used endpoint in majority of the clinical trials in dermatology. The primary and secondary endpoint that is mainly used to assess the majority of trial outcomes is safety.

Scope

- Data and analysis on the marketed products and analysis of their efficacy and safety details.
- Analysis of the five major dermatological disorders which include Alopecia, Acne Vulgaris, Herpes Zoster, Candidiasis and Atopic Dermatitis.
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Also analysis of terminated trials is included in this chapter. Only industry sponsored studies are included in the report.
- Analysis on most promising molecules of five major dermatological disorders with emphasis on their efficacy and safety details.
- Company profiling talks in detail about the companies, which are strong in the market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with increased efficiency and better safety profiles.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.